REVOLUTIONIZING THE
TREATMENT FOR PN
- First and only therapy to target
IL-4Rα, thereby specifically inhibiting
IL-4 and IL-13 signaling1
The mechanism of dupilumab action has not been definitively established.
SEE HOW IT WORKSExtensive Real-World
Experience ACROSS DUPIXENT
In the us, studied in 17 pivotal trials across 5 indications2
Globally,
≈800,000
patients on DUPIXENT
therapy across 5
indications3,a
aThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈10% of this worldwide patient number. Data through December 2023.
First fda-approved therapy for treatment of adults with pn
for first-line use regardless of disease severity
REVOLUTIONIZING THE
PROVEN ITCH REDUCTION
AND NODULE CLEARANCE
- For first-line use regardless of disease severity
- Itch reduction and nodule clearance at Week 24 in some adults with PN
DEMONSTRATED
SAFETY PROFILE
- Most common adverse reactions (incidence ≥2%) in adult patients with prurigo nodularis are nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea1
SAFETY PROFILE
OTHER CONSIDERATIONS
NOT AN
IMMUNOSUPPRESSANT OR
A STEROID1
NO INITIAL LAB TESTING OR ONGOING
LAB MONITORING
according to the Prescribing Information1
NO boxed warning1
Please see additional Warnings and
Precautions in the Prescribing Information
and Important Safety Information throughout. below.
NO KNOWN DRUG‑TO‑DRUG
INTERACTIONS1
Not metabolized through the liver or excreted through the kidneys
- Not metabolized through the liver or excreted through the kidneys
Select important safety information
WARNINGS AND PRECAUTIONS
Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, acute generalized exanthematous pustulosis (AGEP), serum
sickness
or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been
reported. A case of AGEP was reported in an adult subject who participated in the bullous pemphigoid development program. If a clinically
significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.
PRESCRIBED
BIOLOGIC
BY DERMATOLOGISTS2,a
MORE THAN
1 MILLION PATIENTS
On therapy across approved
indications worldwide2,b
BEST ACCESS
among specialty systemic
therapies indicated
in PN2,c-e
YOUR FIRST-LINE SYSTEMIC CHOICE
Now approved for 4 indications in dermatology
DUPIXENT provides the best access among specialty systemic therapies indicated for PN2,c-e
Most efficient path to starting treatment for most patientsf ≈98% of commercial PN patients (18+ years of age) nationally are covered for DUPIXENT
What does PN look like on different skin tones?
- aIQVIA SMART Portal Patient Insights as of June 2025.
- bThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 11 countries (Brazil, Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈12% of this worldwide patient number. This number is composed of the following US approved indications: AD, asthma, BP, COPD, CRSwNP, CSU, PN, and EoE. Data through June 2025.
- c≈98% of commercial PN patients (18+ years of age) nationally are covered for DUPIXENT. ≈91% of commercial patient lives have to fail only 1 or 2 prescription topical treatments.
- dMMIT Analysis, June 2025. Analysis included DUPIXENT, tralokinumab, upadacitinib, abrocitinib, lebrikizumab, and nemolizumab.
- eBased on available published commercial UM coverage data.
- fLeast step edits to biologics and oral JAKis in PN.
- AD, atopic dermatitis; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; CSU, chronic spontaneous urticaria; EoE, eosinophilic esophagitis.